Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study

Alexandra L. Dima (Corresponding Author), Eric Van Ganse, Gertraud Stadler, Marijn de Bruin, the ASTRO-LAB group

Research output: Contribution to journalArticle

Abstract

Inhaled corticosteroids (ICS) adherence is important for asthma management. Current evidence on the impact of ICS adherence on outcomes is mostly based on correlational analyses of between-person data. Although it is widely acknowledged that asthma outcomes fluctuate over time, evidence on predictors of within-person change is scarce. We aimed to quantify these fluctuations and the longitudinal relationships between ICS adherence and outcomes at both between- and within-person levels.


A prospective cohort of persistent asthma patients in France and the United Kingdom (N = 847, age 6−40 years) provided 3756 reports over up to 2 years via computer-assisted telephone interviews and text messages on ICS adherence, asthma control, reliever medication use, and exacerbations. We examined adherence−outcome relations via longitudinal models, controlling for confounders, including severity.


Considerable within-person variability was found for exacerbations (91%), asthma control (59%), and reliever use (52%); 431 (11.5%) reports signalled exacerbations and 2046 (54.5%) poor control. At between-person level, patients with higher average adherence were more likely to report asthma control (OR=1.25 95%CI[1.06−1.47]) but not asthma exacerbations (OR=0.99 [0.87−1.12] or lower reliever use (b=-.0004 [-0.089−0.088]). At within-person level, higher-than-usual adherence was associated with higher concomitant reliever use (b=0.092 [0.053−0.131]) and lower subsequent reliever use (b=-0.047 [- 0.005− -0.088]); it was unrelated to asthma control (OR=0.93 [0.84−1.02]) or exacerbations (OR=1.04 [0.94−1.16]).


Patients maintaining high ICS adherence over time have better asthma control. Temporarily increasing ICS adherence tends to be simultaneous to higher reliever use and reduces reliever use later on. Causes of within-person variation in outcomes require more investigation.
Original languageEnglish
JournalEuropean Respiratory Journal
Publication statusAccepted/In press - 16 Sep 2019

Fingerprint

Adrenal Cortex Hormones
Cohort Studies
Asthma
Text Messaging
France
Interviews

Keywords

  • asthma
  • adherence to medications
  • inhaled corticosteroids
  • asthma control
  • asthma exacerbations
  • routine care

Cite this

Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study. / Dima, Alexandra L. (Corresponding Author); Van Ganse, Eric; Stadler, Gertraud; de Bruin, Marijn; the ASTRO-LAB group.

In: European Respiratory Journal, 16.09.2019.

Research output: Contribution to journalArticle

@article{f8a4276214f34b8194e6c8f89106f8f1,
title = "Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study",
abstract = "Inhaled corticosteroids (ICS) adherence is important for asthma management. Current evidence on the impact of ICS adherence on outcomes is mostly based on correlational analyses of between-person data. Although it is widely acknowledged that asthma outcomes fluctuate over time, evidence on predictors of within-person change is scarce. We aimed to quantify these fluctuations and the longitudinal relationships between ICS adherence and outcomes at both between- and within-person levels.A prospective cohort of persistent asthma patients in France and the United Kingdom (N = 847, age 6−40 years) provided 3756 reports over up to 2 years via computer-assisted telephone interviews and text messages on ICS adherence, asthma control, reliever medication use, and exacerbations. We examined adherence−outcome relations via longitudinal models, controlling for confounders, including severity.Considerable within-person variability was found for exacerbations (91{\%}), asthma control (59{\%}), and reliever use (52{\%}); 431 (11.5{\%}) reports signalled exacerbations and 2046 (54.5{\%}) poor control. At between-person level, patients with higher average adherence were more likely to report asthma control (OR=1.25 95{\%}CI[1.06−1.47]) but not asthma exacerbations (OR=0.99 [0.87−1.12] or lower reliever use (b=-.0004 [-0.089−0.088]). At within-person level, higher-than-usual adherence was associated with higher concomitant reliever use (b=0.092 [0.053−0.131]) and lower subsequent reliever use (b=-0.047 [- 0.005− -0.088]); it was unrelated to asthma control (OR=0.93 [0.84−1.02]) or exacerbations (OR=1.04 [0.94−1.16]).Patients maintaining high ICS adherence over time have better asthma control. Temporarily increasing ICS adherence tends to be simultaneous to higher reliever use and reduces reliever use later on. Causes of within-person variation in outcomes require more investigation.",
keywords = "asthma, adherence to medications, inhaled corticosteroids, asthma control, asthma exacerbations, routine care",
author = "Dima, {Alexandra L.} and {Van Ganse}, Eric and Gertraud Stadler and {de Bruin}, Marijn and {the ASTRO-LAB group}",
note = "Funding: The research leading to these results has received funding from the European Community 7th Framework (FP7/2007-2013) under grant agreement n°282593, and H2020 programme (MSCA-IF) under GA n°706028 for AD during manuscript preparation.",
year = "2019",
month = "9",
day = "16",
language = "English",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",

}

TY - JOUR

T1 - Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study

AU - Dima, Alexandra L.

AU - Van Ganse, Eric

AU - Stadler, Gertraud

AU - de Bruin, Marijn

AU - the ASTRO-LAB group

N1 - Funding: The research leading to these results has received funding from the European Community 7th Framework (FP7/2007-2013) under grant agreement n°282593, and H2020 programme (MSCA-IF) under GA n°706028 for AD during manuscript preparation.

PY - 2019/9/16

Y1 - 2019/9/16

N2 - Inhaled corticosteroids (ICS) adherence is important for asthma management. Current evidence on the impact of ICS adherence on outcomes is mostly based on correlational analyses of between-person data. Although it is widely acknowledged that asthma outcomes fluctuate over time, evidence on predictors of within-person change is scarce. We aimed to quantify these fluctuations and the longitudinal relationships between ICS adherence and outcomes at both between- and within-person levels.A prospective cohort of persistent asthma patients in France and the United Kingdom (N = 847, age 6−40 years) provided 3756 reports over up to 2 years via computer-assisted telephone interviews and text messages on ICS adherence, asthma control, reliever medication use, and exacerbations. We examined adherence−outcome relations via longitudinal models, controlling for confounders, including severity.Considerable within-person variability was found for exacerbations (91%), asthma control (59%), and reliever use (52%); 431 (11.5%) reports signalled exacerbations and 2046 (54.5%) poor control. At between-person level, patients with higher average adherence were more likely to report asthma control (OR=1.25 95%CI[1.06−1.47]) but not asthma exacerbations (OR=0.99 [0.87−1.12] or lower reliever use (b=-.0004 [-0.089−0.088]). At within-person level, higher-than-usual adherence was associated with higher concomitant reliever use (b=0.092 [0.053−0.131]) and lower subsequent reliever use (b=-0.047 [- 0.005− -0.088]); it was unrelated to asthma control (OR=0.93 [0.84−1.02]) or exacerbations (OR=1.04 [0.94−1.16]).Patients maintaining high ICS adherence over time have better asthma control. Temporarily increasing ICS adherence tends to be simultaneous to higher reliever use and reduces reliever use later on. Causes of within-person variation in outcomes require more investigation.

AB - Inhaled corticosteroids (ICS) adherence is important for asthma management. Current evidence on the impact of ICS adherence on outcomes is mostly based on correlational analyses of between-person data. Although it is widely acknowledged that asthma outcomes fluctuate over time, evidence on predictors of within-person change is scarce. We aimed to quantify these fluctuations and the longitudinal relationships between ICS adherence and outcomes at both between- and within-person levels.A prospective cohort of persistent asthma patients in France and the United Kingdom (N = 847, age 6−40 years) provided 3756 reports over up to 2 years via computer-assisted telephone interviews and text messages on ICS adherence, asthma control, reliever medication use, and exacerbations. We examined adherence−outcome relations via longitudinal models, controlling for confounders, including severity.Considerable within-person variability was found for exacerbations (91%), asthma control (59%), and reliever use (52%); 431 (11.5%) reports signalled exacerbations and 2046 (54.5%) poor control. At between-person level, patients with higher average adherence were more likely to report asthma control (OR=1.25 95%CI[1.06−1.47]) but not asthma exacerbations (OR=0.99 [0.87−1.12] or lower reliever use (b=-.0004 [-0.089−0.088]). At within-person level, higher-than-usual adherence was associated with higher concomitant reliever use (b=0.092 [0.053−0.131]) and lower subsequent reliever use (b=-0.047 [- 0.005− -0.088]); it was unrelated to asthma control (OR=0.93 [0.84−1.02]) or exacerbations (OR=1.04 [0.94−1.16]).Patients maintaining high ICS adherence over time have better asthma control. Temporarily increasing ICS adherence tends to be simultaneous to higher reliever use and reduces reliever use later on. Causes of within-person variation in outcomes require more investigation.

KW - asthma

KW - adherence to medications

KW - inhaled corticosteroids

KW - asthma control

KW - asthma exacerbations

KW - routine care

M3 - Article

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

ER -